Double Blind, Randomized, Placebo-controlled, Multicenter Pilot Study on Efficacy and Safety of CBLB612 Following Single Administration for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Myelosuppressive Chemotherapy
Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety of CBLB612 following single administration for neutropenia prophylaxis in breast cancer patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
100 Clinical Results associated with BioLab 612 LLC
0 Patents (Medical) associated with BioLab 612 LLC
100 Deals associated with BioLab 612 LLC
100 Translational Medicine associated with BioLab 612 LLC